State of the art and future perspectives of new radionuclides in Nuclear Medicine

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2025-01-01 DOI:10.1016/j.remnie.2025.500082

J.J. Rosales , M.L. Domínguez , L. Sancho , E. Prieto , M. de Arcocha , I. Torres , A. Roteta , R. Ramos , G. Quincoces

{"title":"State of the art and future perspectives of new radionuclides in Nuclear Medicine","authors":"J.J. Rosales , M.L. Domínguez , L. Sancho , E. Prieto , M. de Arcocha , I. Torres , A. Roteta , R. Ramos , G. Quincoces","doi":"10.1016/j.remnie.2025.500082","DOIUrl":null,"url":null,"abstract":"<div><div>This continuing education analyzes recent advances in Nuclear Medicine focused on the development of new radiopharmaceuticals that improve both the diagnosis and treatment of complex diseases. The focus is on teragnosis, which combines diagnosis and treatment by means of pairs of radiopharmaceuticals directed to the same molecular target, which allows the personalization of treatments.</div><div>This first part specifically reviews the teragnostic pairs copper-64/copper-67, lead-212/lead-203 and scandium-44/scandium-47, highlighting their physical characteristics, methods of production and potential clinical applications.</div><div>Despite the challenges in their production, their versatility and effectiveness are driving their clinical application in oncology and other diseases. The text also addresses the development of new radiopharmaceuticals and their impact on precision medicine, pointing out future directions and opportunities for research in this field.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 1","pages":"Article 500082"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de medicina nuclear e imagen molecular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2253808925000011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

This continuing education analyzes recent advances in Nuclear Medicine focused on the development of new radiopharmaceuticals that improve both the diagnosis and treatment of complex diseases. The focus is on teragnosis, which combines diagnosis and treatment by means of pairs of radiopharmaceuticals directed to the same molecular target, which allows the personalization of treatments.

This first part specifically reviews the teragnostic pairs copper-64/copper-67, lead-212/lead-203 and scandium-44/scandium-47, highlighting their physical characteristics, methods of production and potential clinical applications.

Despite the challenges in their production, their versatility and effectiveness are driving their clinical application in oncology and other diseases. The text also addresses the development of new radiopharmaceuticals and their impact on precision medicine, pointing out future directions and opportunities for research in this field.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

核医学中新型放射性核素的现状和未来展望。

这一继续教育分析了核医学的最新进展，重点是开发新的放射性药物，改善复杂疾病的诊断和治疗。重点是畸形诊断，它将诊断和治疗结合起来，通过针对同一分子靶点的成对放射性药物，从而实现治疗的个性化。本文第一部分详细介绍了铜64/铜67、铅212/铅203和钪44/钪47这三种诊断配对，重点介绍了它们的物理特性、制备方法和潜在的临床应用。尽管在生产中存在挑战，但其多功能性和有效性正在推动其在肿瘤和其他疾病中的临床应用。本文还讨论了新的放射性药物的发展及其对精密医学的影响，指出了该领域研究的未来方向和机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Revista espanola de medicina nuclear e imagen molecular

自引率

0.00%

发文量